SYN-Tech Chem & Pharm Co Ltd
SYN-TECH Chem. & Pharm. Co., Ltd. manufactures and sells active pharmaceutical ingredients (APIs) in Taiwan, Asia, Europe, the Americas, and internationally. The company offers test drugs and surfactants, as well as various Chinese, Western, and animal medicines. It also provides products in various categories, such as anticoagulant, attention deficit hyperactivity disorder, skeletal muscle relax… Read more
SYN-Tech Chem & Pharm Co Ltd (1777) - Net Assets
Latest net assets as of December 2025: NT$2.59 Billion TWD
Based on the latest financial reports, SYN-Tech Chem & Pharm Co Ltd (1777) has net assets worth NT$2.59 Billion TWD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$2.96 Billion) and total liabilities (NT$369.57 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$2.59 Billion |
| % of Total Assets | 87.51% |
| Annual Growth Rate | 10.33% |
| 5-Year Change | 30.6% |
| 10-Year Change | 152.09% |
| Growth Volatility | 16.69 |
SYN-Tech Chem & Pharm Co Ltd - Net Assets Trend (2015–2025)
This chart illustrates how SYN-Tech Chem & Pharm Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for SYN-Tech Chem & Pharm Co Ltd (2015–2025)
The table below shows the annual net assets of SYN-Tech Chem & Pharm Co Ltd from 2015 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | NT$2.59 Billion | +1.17% |
| 2024-12-31 | NT$2.56 Billion | +10.48% |
| 2023-12-31 | NT$2.32 Billion | +5.37% |
| 2022-12-31 | NT$2.20 Billion | +10.89% |
| 2021-12-31 | NT$1.98 Billion | +59.88% |
| 2020-12-31 | NT$1.24 Billion | +6.93% |
| 2019-12-31 | NT$1.16 Billion | +5.58% |
| 2018-12-31 | NT$1.10 Billion | +10.30% |
| 2017-12-31 | NT$996.24 Million | -3.05% |
| 2016-12-31 | NT$1.03 Billion | +6.03% |
| 2015-12-31 | NT$969.06 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to SYN-Tech Chem & Pharm Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 148.4% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | NT$887.33 Million | 34.26% |
| Other Components | NT$1.70 Billion | 65.74% |
| Total Equity | NT$2.59 Billion | 100.00% |
SYN-Tech Chem & Pharm Co Ltd Competitors by Market Cap
The table below lists competitors of SYN-Tech Chem & Pharm Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Accuray Incorporated
NASDAQ:ARAY
|
$45.01 Million |
|
SunWay Biotech Co., LTD.
TWO:1271
|
$45.04 Million |
|
Southern Rubber Industry JSC
VN:CSM
|
$45.04 Million |
|
Coxon Precise Industrial Co Ltd
TW:3607
|
$45.04 Million |
|
DURECT CORP. DL-001
F:DC8A
|
$44.99 Million |
|
IF Bancorp Inc
NASDAQ:IROQ
|
$44.99 Million |
|
Multitude SE
LSE:0R4W
|
$44.97 Million |
|
GAMING INNOVATION DL 1
F:GI11
|
$44.96 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in SYN-Tech Chem & Pharm Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,560,215,000 to 2,590,282,000, a change of 30,067,000 (1.2%).
- Net income of 261,609,000 contributed positively to equity growth.
- Dividend payments of 236,336,000 reduced retained earnings.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$261.61 Million | +10.1% |
| Dividends Paid | NT$236.34 Million | -9.12% |
| Other Changes | NT$4.79 Million | +0.19% |
| Total Change | NT$- | 1.17% |
Book Value vs Market Value Analysis
This analysis compares SYN-Tech Chem & Pharm Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.24x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 2.18x to 1.24x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | NT$33.01 | NT$72.00 | x |
| 2017-12-31 | NT$32.01 | NT$72.00 | x |
| 2018-12-31 | NT$35.30 | NT$72.00 | x |
| 2019-12-31 | NT$37.26 | NT$72.00 | x |
| 2020-12-31 | NT$39.82 | NT$72.00 | x |
| 2021-12-31 | NT$56.21 | NT$72.00 | x |
| 2022-12-31 | NT$49.25 | NT$72.00 | x |
| 2023-12-31 | NT$51.86 | NT$72.00 | x |
| 2024-12-31 | NT$57.41 | NT$72.00 | x |
| 2025-12-31 | NT$58.09 | NT$72.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently SYN-Tech Chem & Pharm Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 10.10%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 20.12%
- • Asset Turnover: 0.44x
- • Equity Multiplier: 1.14x
- Recent ROE (10.10%) is below the historical average (12.64%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | 16.12% | 22.86% | 0.56x | 1.26x | NT$59.33 Million |
| 2016 | 15.42% | 20.67% | 0.60x | 1.25x | NT$55.71 Million |
| 2017 | 6.00% | 8.60% | 0.45x | 1.56x | NT$-39.85 Million |
| 2018 | 14.01% | 19.62% | 0.43x | 1.66x | NT$44.11 Million |
| 2019 | 13.75% | 16.85% | 0.51x | 1.60x | NT$43.46 Million |
| 2020 | 15.05% | 18.98% | 0.55x | 1.44x | NT$62.69 Million |
| 2021 | 8.93% | 19.83% | 0.31x | 1.46x | NT$-21.18 Million |
| 2022 | 13.43% | 29.94% | 0.35x | 1.26x | NT$75.36 Million |
| 2023 | 10.83% | 22.52% | 0.38x | 1.25x | NT$19.27 Million |
| 2024 | 15.36% | 31.27% | 0.44x | 1.11x | NT$137.26 Million |
| 2025 | 10.10% | 20.12% | 0.44x | 1.14x | NT$2.58 Million |
Industry Comparison
This section compares SYN-Tech Chem & Pharm Co Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,052,446,444
- Average return on equity (ROE) among peers: 7.41%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| SYN-Tech Chem & Pharm Co Ltd (1777) | NT$2.59 Billion | 16.12% | 0.14x | $45.00 Million |
| Synbio Tech Inc. (1295) | $863.17 Million | 18.53% | 0.78x | $21.14K |
| Apex Biotechnology Corp (1733) | $1.92 Billion | 19.33% | 0.42x | $65.42 Million |
| Sinphar Pharmaceutical Co Ltd (1734) | $1.77 Billion | 2.60% | 1.02x | $129.70 Million |
| Panion & BF Biotech Inc (1760) | $835.25 Million | 10.84% | 0.49x | $122.27 Million |
| Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) | $1.62 Billion | 0.90% | 0.98x | $40.94 Million |
| Level Biotechnology (3118) | $542.40 Million | 10.78% | 0.50x | $22.42 Million |
| GenMont Biotech Inc (3164) | $737.87 Million | 20.00% | 0.85x | $30.93 Million |
| Medigen Biotechnology (3176) | $650.39 Million | 0.00% | 0.08x | $90.59 Million |
| Sagittarius Life Science (3205) | $531.71 Million | -16.25% | 0.27x | $56.62 Million |